Carbetocin
যখন এপিডুরাল বা মেরুদণ্ডের অ্যানেস্থেশিয়ার অধীনে সিজারিয়ান সেকশনের মাধ্যমে শিশুর প্রসব সম্পন্ন করা তখন ১০০ মাইক্রগ্রামের কার্বেটোসিনের একটি একক ডোজের ইন্ট্রাভেনাস ইনজেকশন একটি বোলাস ইনজেকশন দ্বারা ধীরে ধীরে ১ মিনিটের বেশি সময় নিয়ে প্রবেশ করান হয়। কার্বেটোসিন শুধুমাত্র একক ডোজ হিসাবে ব্যবহার করা হয়।
কার্বেটোসিন নির্দেশিত-এপিডুরাল বা স্পাইনাল অ্যানেস্থেশিয়ার অধীনে ইলেকটিভ সিজারিয়ান সেকশনের মাধ্যমে শিশুর প্রসবের পর জরায়ুর অ্যাটনি এবংপ্রসবোত্তর রক্তক্ষরণ (অতিরিক্ত রক্তপাত) প্রতিরোধের জন্য
১০-৪০% রোগী বমি বমি ভাব, বমি, পেটে ব্যথা, ত্বকে চুলকানি, শরীরের তাপমাত্রা বৃদ্ধি, কাঁপুনি এবং দুর্বলতা অনুভব করেছেন। বিরল পার্শ্ব প্রতিক্রিয়ায় (১-৫% রোগীদের) পিঠে ব্যথা, মাথা ঘোরা, ধাতব স্বাদ, রক্তাল্পতা, ঘাম, বুকে ব্যথা, ডিসপনিয়া, ঠান্ডা লাগা, ট্যকিকার্ডিয়া এবং উদ্বেগ অন্তর্ভুক্ত।
২-৮ ডিগ্রি সেলসিয়াসে সংরক্ষণ করুন। আলো থেকে দূরে থাকুন। একবার অ্যাম্পুল খোলা হয়ে গেলে, পণ্যটি অবিলম্বে ব্যবহার করা উচিত।
Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin; it causes contraction of the uterus. Carbetocin binds to oxytocin receptors present on the smooth musculature of the uterus, resulting in rhythmic contractions of the uterus, increased frequency of existing contractions, and increased uterine tone. The oxytocin receptor content of the uterus is very low in the non-pregnant state, and increases during pregnancy, reaching a peak at the time of delivery.
A single intravenous dose of 100 mcg of carbetocin injection is administered by bolus injection, slowly over 1 minute, only when infant delivery has been completed by caesarean section under epidural or spinal anaesthesia. carbetocin is to be used as a single dose only.
No specific drug interactions have been reported with Oxagon.
Because of its long duration of action relative to oxytocin, uterine contractions produced by carbetocin cannot be stopped by simply discontinuing the medication. Therefore, carbetocin should not be administered prior to delivery of the infant for any reason, including elective or medical induction of labour. Inappropriate use of carbetocin during pregnancy could theoretically mimic the symptoms of oxytocin overdosage, including hyperstimulation of the uterus with strong (hypertonic) or prolonged (tetanic) contractions, tumultuous labour, uterine rupture, cervical and vaginal lacerations, postpartum haemorrhage, utero-placental hypoperfusion and variable deceleration of foetal heart, foetal hypoxia, hypercapnia, or death. Carbetocin should not be used in patients with a history of hypersensitivity to oxytocin or carbetocin. Carbetocin should not be used in patients with cardio vascular disease, especially coronary artery disease, valvular heart disease, cardiomyopathy and heart failure. Carbetocin is not intended for use in children.
10-40% of patients experienced nausea, vomiting, abdominal pain, itching skin, increased body temperature, trembling and weakness. Infrequent adverse events (1-5% of patients) included back pain, dizziness, metallic taste, anaemia, sweating, chest pain, dyspnoea, chills, tachycardia and anxiety.
Use of carbetocin injection is contraindicated during pregnancy. Small amounts of carbetocin has been shown to cross over from plasma into the breast milk of nursing women. The small amount of carbetocin ingested by infant would not be expected to present a significant safety concern.
In patients who may not have an adequate uterine contraction after a single injection of Oxagon, more aggressive treatment with additional doses of oxytocin or ergometrine is warranted.As Oxagon is closely related in structure to oxytocin, hyponatraemia may occur.Oxagon should be used cautiously in the presence of epilepsy, migraine, asthma or any state in which a rapid addition to extracellular water may produce hazard for an already overburdened system.Patients with eclampsia and pre-eclampsia should be monitored for changes in blood pressure.Oxagon is not recommended for use in elderly patients.
Overdosage of Oxagon can be expected to produce enhanced pharmacological effects associated with uterine hyperactivity and pain. Treatment consists of symptomatic and supportive management.
Drugs acting on the Uterus
Store at 2-8°C. Do not freeze. Keep away from light. Once the ampoule has been opened, the product should be used immediately.
{'Indications': 'Oxagon is indicated for the prevention of uterine atony and postpartum haemorrhage (excessive bleeding) following delivery of the infant by elective caesarean section under epidural or spinal anaesthesia.'}